Market Update - All End of CY24 Milestones Attained
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company is progressing towards the commercial launch of its next-generation colorectal cancer diagnostic, with plans for further testing and clinical validation. Additionally, Rhythm has engaged consultants to assist with regulatory pathways in key markets, aiming for a commercial rollout in the second half of the calendar year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Strong Demand in Share Placement to Raise $3.5 million
- Receipt of Research & Development Tax Incentive
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
- Board Renewal / Composition Update
- Platform Expansion - Gastric Cancer Diagnostic Test Update
Later from Rhythm Biosciences
- Pause in Trading
- RHY Acquires Genetype Genetic Risk Assessment Business
- Completion of Genetype Risk Assessment Portfolio Acquisition
- About the Genetype Acquisition
- Quarterly Activities Report and Appendix 4C - Dec24
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences